Duke Scientists Explore New Prostate Cancer Treatment

Duke University researchers are studying a promising new treatment for prostate cancer that may help patients live significantly longer. The treatment combines enzalutamide with standard hormonal therapy. According to WCCB, this combination extended survival by 30 percent. For patients with high-volume disease, life expectancy increased from four to seven years. Among those with low-volume disease, over 75 percent lived beyond five years, showing strong potential for improved long-term outcomes.